Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate

Urology

Volumn 48, Issue 2, 1996, Pages 240-248

  Lerner, Seth E ^b   Jacobsen, Steven J ^b   Lilja, Hans ^b   Bergstralh, Erik J ^b   Ransom, Jeanine ^b   Klee, George G ^b   Piironen, Timo ^b   Blute, Michael L ^b   Lieber, Michael M ^b   Zincke, Horst ^b   Pettersson, Kim ^b   Peterson, Diane ^b   Oesterllng, Joseph E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; STATISTICAL ANALYSIS;

EID: 0038193994     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00159-8     Document Type: Article

References (30)

1. 1. Wang MC, Valenzuela LA, Murphy GP, and Chu TM: Purification of a human prostate specific antigen. Invest Urol 17: 159-163, 1979.
2. 2. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostrate. J Urol 145: 907-923, 1991.
3. 3. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899-1903, 1985.
4. 4. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, and Alfthan O: A complex between prostate specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
5. 5. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, and Lovgren T: Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
6. 6. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M-T, Cockett AT, Abrahamsson P-A, and Lilja H: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
7. 7. Lilja H, Bork T, Abrahamsson P-A, Stenman UH, Shaw N, Dowell B, Oesterling JE, Pettersson K, Piironen T, and Lovgren T: Improved separation between normals, benign hyperplasia (BPH) and carcinoma of the prostate ( CaP ) by measuring free (F), complexed (c) and total concentrations (T) of prostate specific antigen (abstract no. 692). J Urol 151: 400A, 1994.
8. 8. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
9. 9. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
10. 10. Catalona WJ, and Stein AJ: Staging errors in clinically localized prostatic cancer. J Urol 127: 452-455, 1982.
11. 11. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized disease (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
12. 12. Zincke H, Blute ML, Fallen MJ, and Farrow GM: Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol 146: 1053-1058, 1991.
13. 13. Gleason DF: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (Ed): Urologic Pathology: The Prostate. Philadelphia, Lea and Febiger, 1977, pp 171-197.
14. 14. Montie JE: 1992 staging system for prostate cancer. Semin Urol 11: 10-13, 1992.
15. 15. Winkler HZ, Rainwater LM, Myers RP, Farrow GM, Therneau TM, Zincke H, and Leiber MM: Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 63: 103-112, 1988.
16. 16. Paulson DF, Moul JW, and Walther PJ: Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 144: 1180-1184, 1990.
17. 17. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, and Zincke H: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42: 283-291, 1993.
18. 18. Hudson MA, Bahnson RR, and Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142: 1011-1017, 1989.
19. 19. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, and Vesella R: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141: 873-879, 1989.
20. 20. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, and Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
21. 21. Kleer E, Larson-Keller JJ, Zincke H, and Oesterling JE: Ability of preoperative serum prostate-specific antigen values to predict pathologic stage and DNA ploidy. Urology 41: 207-216, 1993.
22. 22. Stamey TA, and Kabalin JN: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: I. Untreated patients. J Urol 141: 1070-1075, 1989.
23. 23. Bjork T, Bjartell A, Abrahamsson P-A, Hulkko S, di Sant'agnese A, and Lilja H: Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 43: 427-434, 1994.
24. 24. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, and Lieber MM: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 142: 1262-1265, 1989.
25. 25. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, and Epstein JI: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 153: 1015-1019, 1995.
26. 26. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, and Zincke H: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156: 137-143, 1996.
27. 27. Nativ O, Myers RP, Farrow GM, Therneau TM, Zincke H, and Lieber MM: Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. J Urol 144: 303-306, 1990.
28. 28. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, and Lovgren T: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41: 1115-1120, 1995.
29. 29. Bluestein DL, Bostwick DG, Bergstralh EJ, and Oesterling JE: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 151: 1315-1320, 1994.
30. 30. Blackwell KL, Bostwick DG, Myers RP, Zincke H, and Oesterling JE: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen density. J Urol 151: 1565-1570, 1994.